Mirae Asset Global Investments Co. Ltd. Purchases 559 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 31.6% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 2,330 shares of the company’s stock after acquiring an additional 559 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Nurix Therapeutics were worth $54,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. ProShare Advisors LLC lifted its position in shares of Nurix Therapeutics by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock worth $176,000 after buying an additional 998 shares during the last quarter. ClariVest Asset Management LLC lifted its position in shares of Nurix Therapeutics by 2.9% during the 2nd quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock worth $1,318,000 after buying an additional 1,766 shares during the last quarter. Public Employees Retirement System of Ohio lifted its position in shares of Nurix Therapeutics by 3.7% during the 1st quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company’s stock worth $747,000 after buying an additional 1,820 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Nurix Therapeutics by 299.8% during the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after buying an additional 3,424 shares during the last quarter. Finally, International Assets Investment Management LLC lifted its position in shares of Nurix Therapeutics by 1,098.4% during the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock worth $101,000 after buying an additional 4,119 shares during the last quarter.

Nurix Therapeutics Stock Performance

NASDAQ NRIX opened at $25.43 on Wednesday. Nurix Therapeutics, Inc. has a fifty-two week low of $4.96 and a fifty-two week high of $27.60. The stock has a 50 day simple moving average of $24.21 and a two-hundred day simple moving average of $20.42. The stock has a market cap of $1.80 billion, a P/E ratio of -8.74 and a beta of 2.20.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The firm had revenue of $12.59 million during the quarter, compared to analyst estimates of $13.85 million. Sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently weighed in on NRIX. Royal Bank of Canada dropped their price objective on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Oppenheimer upped their target price on Nurix Therapeutics from $27.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, September 4th. Stephens reaffirmed an “overweight” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a report on Monday, October 14th. Robert W. Baird initiated coverage on Nurix Therapeutics in a report on Friday, September 6th. They issued an “outperform” rating and a $26.00 target price for the company. Finally, HC Wainwright upped their target price on Nurix Therapeutics from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $29.40.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, insider Christine Ring sold 9,870 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $25.01, for a total transaction of $246,848.70. Following the sale, the insider now directly owns 24,592 shares in the company, valued at approximately $615,045.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Nurix Therapeutics news, insider Christine Ring sold 9,870 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $25.01, for a total transaction of $246,848.70. Following the sale, the insider now directly owns 24,592 shares in the company, valued at approximately $615,045.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Gwenn Hansen sold 3,437 shares of the stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $83,519.10. Following the sale, the insider now owns 50,670 shares in the company, valued at approximately $1,231,281. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,321 shares of company stock valued at $1,414,409 in the last 90 days. Corporate insiders own 9.80% of the company’s stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.